Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous …

P Paschka, MC Müller, K Merx, S Kreil, C Schoch… - Leukemia, 2003 - nature.com
A significant proportion of chronic myeloid leukemia (CML) patients achieve a major
cytogenetic remission (MCR) to imatinib therapy after failing interferon (IFN) α-based …
被引用次数：121 相关文章

[引用][C] Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with …

P Paschka, MC Müller, K Merx, S Kreil, C Schoch… - Leukemia, 2003 - cir.nii.ac.jp
Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with
interferon alpha. Low levels of residual disease are associated with continuous remission …
[PDF] researchgate.net

[PDF][PDF] Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with …

Leukemia, 2003 - researchgate.net
A significant proportion of chronic myeloid leukemia (CML) patients achieve a major
cytogenetic remission (MCR) to imatinib therapy after failing interferon (IFN) a-based …

[引用][C] Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with …

P PASCHKA, MC MÜLLER, H GSCHAIDMEIER… - …, 2003 - pascal-francis.inist.fr
Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with
interferon alpha. Low levels of residual disease are associated with continuous remission …

Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous …

P Paschka, MC Muller, K Merx, S Kreil, C Schoch… - Leukemia, 2003 - eprints.soton.ac.uk
A significant proportion of chronic myeloid leukemia (CML) patients achieve a major
cytogenetic remission (MCR) to imatinib therapy after failing interferon (IFN) alpha-based …

Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous …

P Paschka, MC Müller, K Merx, S Kreil… - …, 2003 - pubmed.ncbi.nlm.nih.gov
A significant proportion of chronic myeloid leukemia (CML) patients achieve a major
cytogenetic remission (MCR) to imatinib therapy after failing interferon (IFN) alpha-based …

Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with …

P Paschka, MC Müller, K Merx, S Kreil… - Leukemia …, 2003 - search.ebscohost.com
A significant proportion of chronic myeloid leukemia (CML) patients achieve a major
cytogenetic remission (MCR) to imatinib therapy after failing interferon (IFN) a-based …

Molecular monitoring of response to imatinib (Glivec [R]) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with …

P Paschka, MC Muller, K Merx, S Kreil, C Schoch… - Leukemia, 2003 - go.gale.com
A significant proportion of chronic myeloid leukemia (CML) patients achieve a major
cytogenetic remission (MCR) to imatinib therapy after failing interferon (IFN)[alpha]-based …

Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous …

P Paschka, MC Müller, K Merx, S Kreil, C Schoch… - Leukemia, 2003 - europepmc.org
A significant proportion of chronic myeloid leukemia (CML) patients achieve a major
cytogenetic remission (MCR) to imatinib therapy after failing interferon (IFN) alpha-based …

[引用][C] Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with …

P PASCHKA, MC MÜLLER, K MERX, S KREIL… - …, 2003 - Nature Publishing Group